The FDA approval of Roivant’s brepocitinib for dermatomyositis reinforces how the agency’s decisions in rare autoimmune disease are continuing to shape commercial planning for “spoke” programs licensed from larger pharma partners. Priovant’s deal structure with Pfizer and the first oral approval for this indication bring a new treatment class into the standard-of-care decision tree. While the approval itself is for a rare population, the pipeline implications are broader: it sets expectations for oral, targeted immune modulation in chronic conditions where long-term tolerability is a central differentiator. For Roivant, the clearance supports the company’s strategy to scale rare disease brands through fast transitions from regulatory win to marketplace execution. Clinicians and payers will now focus on comparative effectiveness versus steroids and other immune suppressants, as well as real-world adoption patterns.